Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts

Rameshprabu Nallathambi,1,4 Moran Mazuz,1,9 Aurel Ion,1 Gopinath Selvaraj,1 Smadar Weininger,1 Marcelo Fridlender,1 Ahmad Nasser,1 Oded Sagee,2 Puja Kurnari,1 Diana Nemichenizer,1,3 Maayan Mendelovitz,1,3 Nave Firstein,4 Orly Hanin,4 Fred Konikoff,4,5 Yoram Kapulnik,1 Timna Naftali,4,5 and Hinanit Koltai1,*

Abstract

Introduction: Inflammatory bowel diseases (IBDs) include Crohn's disease, and ulcerative colitis. Cannabis sativa preparations have beneficial effects for IBD patients. However, C. sativa extracts contain hundreds of compounds. Although there is much knowledge of the activity of different cannabinoids and their receptor agonists or antagonists, the cytotoxic and anti-inflammatory activity of whole C. sativa extracts has never been characterized in detail with in vitro and ex vivo colon models.

Material and Methods: The anti-inflammatory activity of C. sativa extracts was studied on three lines of epithelial cells and on colon tissue. C. sativa flowers were extracted with ethanol, enzyme-linked immunosorbent assay was used to determine the level of interleukin-8 in colon cells and tissue biopsies, chemical analysis was performed using high-performance liquid chromatography, mass spectrometry and nuclear magnetic resonance and gene expression was determined by quantitative real-time PCR.

Results: The anti-inflammatory activity of Cannabis extracts derives from D9-tetrahydrocannabinolic acid (THCA) present in fraction 7 (F7) of the extract. However, all fractions of C. sativa at a certain combination of concentrations have a significant increased cytotoxic activity. GPR55 receptor antagonist significantly reduces the anti-inflammatory activity of F7, whereas cannabinoid type 2 receptor antagonist significantly increases HCT116 cell proliferation. Also, cannabidiol (CBD) shows dose dependent cytotoxic activity, whereas anti-inflammatory activity was found only for the low concentration of CBD, and in a bell-shaped rather than dose-dependent manner. Activity of the extract and active fraction was verified on colon tissues taken from IBD patients, and was shown to suppress cyclooxygenase-2 (COX2) and metalloproteinase-9 (MMP9) gene expression in both cell culture and colon tissue.

Conclusions: It is suggested that the anti-inflammatory activity of Cannabis extracts on colon epithelial cells derives from a fraction of the extract that contains THCA, and is mediated, at least partially, via GPR55 receptor. The cytotoxic activity of the C. sativa extract was increased by combining all fractions at a certain combination of concentrations and was partially affected by CB2 receptor antagonist that increased cell proliferation. It is suggested that in a nonpsychoactive treatment for IBD, THCA should be used rather than CBD.

Keywords: cannabinoid receptors; Cannabis; COX2; inflammatory bowel disease; MMP9; THCA

1Institute of Plant Sciences, Agricultural Research Organization, Volcani Center, Rishon LeZion, Israel.
2PLANTEK, Rishon LeZion, Israel.
3The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
4Department of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel.
5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
*The first two authors contributed equally.

© Rameshprabu Nallathambi et al. 2017; Published by Mary Ann Liebert, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

167
**Introduction**

Inflammatory bowel diseases (IBDs), Crohn’s disease (CD), and ulcerative colitis (UC) are characterized by chronic intestinal inflammation. Both diseases are chronic, relapsing, and associated with genetic predisposing backgrounds. Their onset and reactivation are triggered by environmental factors that transiently break the mucosal barrier. This may alter the balance between beneficial and pathogenic enteric bacteria and consequently stimulate immune responses. Both CD and UC patients have activated innate (macrophage, neutrophil) and acquired (T and B cell) immune responses (e.g., Sartor).1

Epithelial cells in the gastrointestinal (GI) tract act as barriers against the intrusion of potentially deleterious luminal substances and microorganisms from the intestinal lumen, and play an important role in inflammatory responses. They express a variety of proinflammatory cytokines, which are upregulated in IBD patients.2 Therapies aimed at downregulating intestinal inflammation utilize both mediator-specific and nonspecific immune suppression, but with potentially considerable side effects.3

Different preparations of marijuana (*Cannabis sativa*) have been used for the treatment of GI problems, such as GI pain, gastroenteritis, and diarrhea.4,5 *C. sativa* contains more than 60 terpenophenolic compounds termed phytocannabinoids (reviewed by Aizpurua-Olaizola et al.6). Of these, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which were discovered about 50 years ago, have been defined as the most active.7–9 Also, it was suggested that combination that exists in the whole extract is more active than a single compound solely (e.g., Russo and Taming).10 Cannabinoids have been previously shown to be immune modulators. They shift the balance of pro- and anti-inflammatory cytokines and act to suppress cell-mediated immunity in different physiological systems.11 For example, Δ9-tetrahydrocannabivarin (THCV) was demonstrated to inhibit nitrite production in macrophages and thereby to play an immunomodulatory role.12

Phytocannabinoids have been shown to exert their anti-inflammatory functions on the GI tract by activating receptors that are part of the endocannabinoid system, mainly the G-protein-coupled cannabinoid receptor type 2 (CB2). In the human colonic epithelial cell line HT29, a number of cannabinoid receptor agonists and antagonists, including the plant-derived THC, have been shown to inhibit tumor necrosis factor alpha (TNFα)-induced interleukin-8 (IL-8) release. This inhibition was antagonized by a CB2 receptor antagonist.13 Later, a third cannabinoid receptor, GPR55, was identified and found to affect GI inflammation.14,15 Cannabinoids have been shown to be effective in a mouse model of colitis.16 Cannabinoids have also been shown to promote wound healing in the GI tract via activation of cannabinoid type 1 (CB1) receptor.17 In addition, we have recently reported clinical data from IBD patients. In a retrospective study, we interviewed 30 CD patients who were licensed to use medical *Cannabis*, while in a prospective trial we randomized 20 CD patients to receive either *Cannabis* or placebo for their IBD. Both revealed beneficial effects.

*Cannabis sativa* extracts contain hundreds of different compounds. The activity of many synthetic or isolated cannabinoids and their receptor agonists or antagonists has been investigated and verified. However, there seems to be an advantage of the unrefined content of the flower extract versus an isolated compound in IBD. For example, standardized *C. sativa* extract with high content of CBD given after the inflammatory insult was shown in an animal model of GI inflammation to attenuate injury and motility, further supporting the rationale of combining CBD with other *Cannabis* compounds.20 Also, in three models of seizure, *Cannabis*-derived botanical drug substances exerted significant anticonvulsant effects and were of similar efficacy with purified cannabidivarin.21

Since we could not find any detailed characterization of the anti-inflammatory activity of the whole *C. sativa* extract on both colonic epithelial cells and tissue derived from IBD patient colon, we decided to study the anti-inflammatory activity of *C. sativa* extracts on these models.

IL-8 was previously shown to be an indicator for the level of IBD-related inflammation in both cell models and in IBD patients (e.g., Refs.13,22–25). Therefore, it was chosen in the present study as the main marker for IBD-related inflammation in cell and colon tissues.

Here we show that the anti-inflammatory activity of *Cannabis* extracts on colon cells derived from Δ9-tetrahydrocannabinolic acid (THCA) present in fraction 7 (F7), while a combination of all fractions of *Cannabis* extract exerts an increased cytotoxic activity. Activity of the extract and the most active fraction was verified on colon tissue taken from IBD patients, and these were shown to suppress cyclooxygenase-2 (COX2) and metalloproteinase-9 (MMP9) gene expression in both cell culture and colon tissue.
Materials and Methods

Extraction of Cannabis
Fresh flowers of *C. sativa* strain AD were harvested from plants. They were either taken immediately for extraction and frozen at −80°C, or baked for 3 h at 150°C before extraction. Fresh and baked *Cannabis* flowers (2 g) were pulverized with liquid nitrogen and ground into a fine powder. Absolute ethanol was added to each tube containing the powder at a sample-to-absolute ethanol ratio of 1:4 (w/v). The tubes were mixed thoroughly on a shaker for 30 min and then the extract was filtered through a filter paper. The filtrate was transferred to new tubes. The solvent was evaporated with a vacuum evaporator. The dried extract was resuspended in 1 mL of absolute methanol and filtered through a 0.45-μm syringe filter. The resuspended extract was diluted as to concentrations indicated in the Results section for each of the experiments and used for the treatment of cell cultures and biopsies in enzyme-linked immunosorbent assay (ELISA) experiments. The crude weight per milliliter for each extract was determined by drying 1 mL of the resuspended and filtered extract.

Chemical characterization

Standard preparation. The cannabinoid standards cannabigerol (CBG), CBD, cannabidiolic acid (CBDA), cannabinol (CBN), cannabigerolic acid (CBGA), THC, cannabichromene (CBC), and THCA were diluted to 10 ppm concentration with methanol and then subjected to high-performance liquid chromatography (HPLC) separation. For quantification of THC and THCA, the standards were dissolved in methanol at different concentrations from 5 to 40 ppm.

Sample preparation. For HPLC, the dry extract was resuspended in 1 mL of methanol and filtered through a 0.45-μm syringe filter (Merck, Darmstadt, Germany). The filtered extract was diluted 10 times with methanol and then separated by HPLC.

HPLC separation. Sample separation was carried out in an UltiMate 3000 HPLC system coupled with WPS-3000(T) autosampler, HPG-3400 pump, and DAD-300 detector. The separation was performed on a Purospher RP-18 end capped column (250 mm × 4.6 mm I.D.; Merck KGaA, Darmstadt, Germany) with a guard column (4 mm × 4 mm I.D.). Solvent gradients were formed by isocratic proportion with 15% solvent A (0.1% acetic acid in water) and 85% solvent B (methanol) at a flow rate of 1.5 mL/min for 35 min. The compound peaks were detected at 220, 240, and 280 nm. The 220-nm peaks were taken for further processing. The extracts were fractionated into nine fractions according to the obtained chromatogram.

Mass spectrometry analysis. Analysis of the fractions was carried out using electrospray ionization (ESI) (quadrupole time-of-flight) 6545 (high resolution; Agilent). The mass spectrometry (MS) conditions were as follows: ESI-positive mode, m/z 50–1500, gas temperature 550°C, injection volume 5 μL, solvent composition 0.1% formic acid in water (46%), acetonitrile (50%), and water (4%; v/v).

Nuclear magnetic resonance analysis. 1H and 13C spectra were recorded in a Bruker Avance-400 instrument (400.1 and 100.6 MHz, respectively) in CDCl3 as the solvent, containing tetramethylsilane as an internal reference, at 300 K. In addition, three 2D experiments were performed: COSY (1H–1H correlation), HMQC (one-bond 1H–13C correlation), and HMBC (long-range 1H–13C correlation).

Determination of anti-inflammatory and cytotoxic activities in HCT116, HT29, and CaCO2 cells

HCT116 (ATCC CCL-247), HT29 (ATCC HTB-38), and CaCO2 (ATCC HTB-37) colon cells were grown at 37°C in a humidified 5% CO2–95% air atmosphere. Cells were maintained in McCoy’s 5a modified medium (HCT116 and HT29) and Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (CaCO2). Cells were seeded, in triplicate, into a 24-well plate at a concentration of 50,000 cells per well in 500 μL of growing media and then incubated for 24 h at 37°C in a humidified 5% CO2–95% air atmosphere. When cell excitation was performed with TNFα (300 ng/mL recombinant human TNFα (PeproTech, Rocky Hill, NJ)), cultures in each well were treated along with 50 μL plant extract, as described above. The supernatant was taken and the levels of IL-8 were measured 4 h after treatment using the commercial Human CXCL8/IL-8 DuoSet ELISA kit (R&D Systems, Minneapolis, MN). As a positive control, dexamethasone (Sigma-Aldrich, St. Louis, MO) at 200 and 400 μM final concentrations was used. The maximum involvement of the receptors (CB1, CB2, and GPR55) was examined by treating the cells with 20 μM of the CB1 receptor antagonist/inverse agonist rimonabant (Abcam, Cambridge, MA), CB2 receptor antagonist/inverse agonist SR144528 (Abcam), and GPR55...
sent, biopsies from inflamed and normal tissue were obtained from 29 patients (16–252 mL) or F7 (from 200 mL crude dry extract/mL of C2F) at 37°C in a humidified 5% CO2–95% air atmosphere. Supernatant (100 µL from each well) was transferred to a 96-well plate and the relative fluorescence at the excitation/emission of 544/590 nm was measured. Values were calculated as percentage of live cells relative to the nontreated (cells without TNFα and treatments) control after reducing autofluorescence of Alamar Blue without cells. For dose–response assays, data points were connected by nonlinear regression lines of the sigmoidal dose–response relationship. GraphPad Prism (version 6 for windows; GraphPad Software, Inc. San Diego) was used to produce dose–response curves and IC50 doses were calculated using nonlinear regression analysis.

Culture of biopsies

Three biopsies from both healthy and inflamed intestine of IBD patients were obtained from 29 patients with either CD or UC scheduled for colonoscopy as deemed necessary by their physician, Helsinki approval no. 0094-16. After obtaining informed consent, biopsies from inflamed and normal tissue were taken and placed in tissue culture media. On receiving the biopsies, phosphate-buffered saline was replaced with 75 µL dispase (StemCell Technologies, Cambridge, United Kingdom) and 150 µL collagenase 1A (StemCell Technologies) solution. Tubes were then incubated at 37°C for 1 h. After incubation, the tubes containing the biopsies were centrifuged at 8000 rpm (11,885 g) for 1 min. Then, the supernatant was removed and tissues were washed three times with Hank’s balanced salt solution. After each wash, tubes were centrifuged as described above. Then, the tissues were placed on a small Petri dish and cut into 2–3 pieces with a clean scalpel. The pieces were then placed on Millicell hydrophilic polystyrene tefluorocellulose tissue culture inserts (Millipore, 30 mm, 0.4 µm). The inserts were placed in six-well plastic tissue culture dishes (Costar 3506) along with 1.5 mL of tissue culture medium (DMEM supplemented with 10% v/v heat-inactivated fetal calf serum, 100 U/mL penicillin, 100 µg/mL streptomycin, 50 µg/mL leupeptin, 1 mM phenylmethylsulfonylfluoride, and 50 µg/mL soybean trypsin inhibitor). When dexamethasone was included in the media, its concentration was 200 µg/mL. This was followed by treating the tissues with extracts as mentioned above, or leaving them untreated (control). The supernatants were taken after overnight incubation and used for determination of IL-8 and IL-6 cytokine profile by measuring the levels with a commercial ELISA kit. Levels of cytokines from inflamed, Cannabis-treated, and nontreated tissue were compared.

Quantitative real-time PCR

Cells were seeded into a six-well plate at a concentration of 1,500,000 cell/mL per well. After 24 h of incubation at 37°C in a humidified 5% CO2–95% air atmosphere, cells were treated with TNFα (final concentration of 1 ng/mL) and incubated overnight under the same conditions. Nontreated cells or cells treated only with TNFα served as negative and positive controls, respectively. Cells were then reincubated for 5 h with C2F (200 µg crude dry extract/mL) or F7 (from 200 µg crude dry extract/mL of C2F) at 37°C in a humidified 5% CO2–95% air atmosphere. The next day, cells were harvested and total RNA was extracted using TRI reagent (Sigma-Aldrich) according to the manufacturer’s protocol. For biopsies, all treatments were added overnight, after which the biopsies were stored at −20°C in RNA Save solution (Biological Industries, Beit Haemek, Israel). RNA was extracted from frozen biopsies. Tissue samples were homogenized with an appropriate homogenizer in TRI reagent, as done for the cells. RNA (50 ng for biopsies: four UC patients and one CD patient) or 2.5 µg (for cells) was reverse-transcribed in a total volume of 20 µL using Maxima reverse transcriptase (Thermo Scientific, Boston, MA) according to the manufacturer’s protocol. All primers were designed using Primer3Plus software. PCR was performed in triplicate using a Rotor-Gene 6000 instrument (Qiagen, Zurich, Switzerland) and Maxima SyGreen Mix (Thermo Scientific) according to the manufacturer’s protocol. The expression of each target gene was normalized to the expression of GAPDH mRNA in the 2ΔΔCt and is presented as the ratio of the target gene to GAPDH mRNA, expressed as 2ΔCt, where Ct is the threshold cycle.
flammation (e.g., Refs.13,22–25). At different concentrations of C2F and C2B (114–207 lM) was inactive in reducing inflammation in colon cell lines. At most examined concentrations C2B had significant cytotoxic activity, whereas C2F did not (Fig. 1B). These results suggest that although the reduction in IL-8 level following treatment with C2B may be derived from cell death, that reduction following treatment with C2F is solely based on anti-inflammatory activity. Similar results on the activity of C2F and C2B were obtained in HT29 and CaCO2 cells (Supplementary Figs. S1 and S2); slightly increased cytotoxicity at the higher concentration was determined for C2F in the CaCO2 cell line (Supplementary Fig. S2). Taken together, results demonstrated the strong, dose-dependent, anti-inflammation activity of C. sativa C2F, mostly absent in C2B.

Chemical composition of C. sativa extracts from fresh and baked flowers
HPLC chromatogram and main active compounds were determined for the anti-inflammation active extract, C2F, and for the inactive extract, C2B (Fig. 2; Table 1). Eight major cannabinoids were identified in the fresh and baked crude extracts at 220 nm. These peaks were identified as CBG, CBD, CBDA, CBN, CBGA, THC, CBC, and THCA, with retention times of 5.9, 6.4, 7.9, 10.9, 11.3, 13.1, 17.5, and 29.3 min, respectively, relative to the HPLC profile of cannabinoid standards (not shown). The levels of CBD, CBN, and THC were 36, 14, and 32 times higher in the C2B versus C2F extract. CBC was not identified in C2F but appeared in C2B. The levels of THCA and CBDA in C2B were reduced 1200 and 1.5 times, respectively, compared to those in C2F (Fig. 2; Table 1), due to decarboxylation of CBDA and THCA during heating (e.g., Smith and Vaughan26).

Identification of an active fraction of the fresh flower extract of C. sativa and determination of activity of combinations of fractions
C2F (at a concentration of 163 µg/mL) was fractionated (Fig. 3A) by HPLC. Fractions were collected and were examined for anti-inflammatory activity, determined as the level of IL-8 in HCT116 cells. One fraction, F7, significantly reduced the level of IL-8 to that of the whole extract treatment (C2F and F1–F9 pooled; Fig. 3B). No significant reduction in IL-8 levels was observed for any of the other fractions (Fig. 3A, B). None of the fractions reduced cell viability, whereas treatment with some showed even increased cell proliferation (e.g., F3, F9; Fig. 3C). Similar results of anti-inflammatory activity were obtained for F7 in HT29 and CaCO2 cells (Supplementary Figs. S1 and S2).

Next, F1–F9 pool-excluding F7 and combined treatment of all fractions, including F7, at different concentrations, were examined on HCT116 cells for anti-inflammatory and cytotoxic activities (Fig. 4). As expected, F7 and C2F had similar anti-inflammatory activity, whereas F1–F9-excluding F7 treatment were inactive. However, once F7 was added to F1–F9-excluding F7 treatment, anti-inflammatory activity was retained (Fig. 4A). As for the cytotoxic activity, a marked induction of cytotoxicity was found for
combined treatment of F1–F9-excluding F7 and addition of F7 at concentrations of 190 and 190 μg/mL, respectively, and even more profoundly, at concentrations of 163 and 190 μg/mL, for F1–F9-excluding F7 and F7, respectively (Fig. 4B).

These results suggest that F7 denotes anti-inflammatory activity in colon cell lines, whereas certain combinations of treatment with all fractions of the extract lead to a significant increase in the cytotoxic activity.

The active fraction of C. sativa extract contains mainly THCA

The chemical composition of the active fraction (F7) was analyzed by HPLC and ESI–MS. F7 was obtained...
as a broad peak in the HPLC chromatogram. To analyze its structure and verify its purity, it was analyzed at different dilutions, in comparison to a THCA standard. The results suggested that F7 is THCA (Fig. 5). ESI–MS results further confirmed that F7 contains THCA: $C_{22}H_{30}O_4$ (358.214); $m/z$ (MH$^+$) 359.222, (MNa$^+$) 381.203. $^1$H and $^{13}$C spectra were taken to verify the exact structure and determine the purity of F7. The nuclear magnetic resonance results showed that F7 is indeed THCA, at over 90% purity.

**Table 1. High-Performance Liquid Chromatography Peak Area and Percentage of Area for Ethanol Extract of Cannabis sativa Fresh (C2F) and Baked (C2B) Flowers**

<table>
<thead>
<tr>
<th>RT (Min)</th>
<th>C2F</th>
<th>Area (%)</th>
<th>C2B</th>
<th>Area (%)</th>
<th>Identified compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.604</td>
<td>7,279,491</td>
<td>0.61</td>
<td>4,834,101</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>4.015</td>
<td>15,943,959</td>
<td>1.33</td>
<td>19,329,498</td>
<td>2.52</td>
<td></td>
</tr>
<tr>
<td>5.947</td>
<td>5,640,210</td>
<td>0.47</td>
<td>9,625,348</td>
<td>1.26</td>
<td></td>
</tr>
<tr>
<td>6.466</td>
<td>3,614,080</td>
<td>0.30</td>
<td>8,435,176</td>
<td>11.00</td>
<td></td>
</tr>
<tr>
<td>7.996</td>
<td>14,896,186</td>
<td>1.24</td>
<td>6,041,859</td>
<td>0.79</td>
<td></td>
</tr>
<tr>
<td>10.931</td>
<td>115,095,840</td>
<td>9.61</td>
<td>68,550,632</td>
<td>8.94</td>
<td></td>
</tr>
<tr>
<td>11.339</td>
<td>3,592,090</td>
<td>0.30</td>
<td>32,233,628</td>
<td>4.20</td>
<td></td>
</tr>
<tr>
<td>13.146</td>
<td>25,572,280</td>
<td>2.13</td>
<td>518,303,552</td>
<td>67.59</td>
<td></td>
</tr>
<tr>
<td>17.575</td>
<td>0</td>
<td>0.00</td>
<td>22,981,120</td>
<td>3.00</td>
<td></td>
</tr>
<tr>
<td>29.373</td>
<td>1,006,329,152</td>
<td>84.01</td>
<td>544,761</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>1,197,903,288</td>
<td>100.00</td>
<td>766,803,675</td>
<td>100.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RT, retention time; CBG, cannabigerol; CBD, cannabidiol; CBDA, cannabidiolic acid; CBN, cannabinol, CBGA, cannabigerolic acid; THC, Δ9-tetrahydrocannabinol; CBC, cannabichromene; THCA, Δ9-tetrahydrocannabinolic acid.
FIG. 3. (A) HPLC profile of fractions of *C. sativa* ethanolic extract (C2F). HPLC profile was obtained from isocratic elution with a mixture of 15% water containing 0.1% acetic acid (solvent A) and 85% MeOH (solvent B) for a total run time of 40 min at 220 nm. The sample was injected at a concentration of 0.1 mg crude dried extract/mL in a volume of 50 µL per cycle. Fractions were collected every 2 min. F1–F9 represent the nine fractions collected by HPLC. (B) Anti-inflammatory activity of *C. sativa* ethanolic extracts (C2F; 163 µg/mL), fractions F1–F9 pooled together (HPLC fractions of C2F at concentrations of 163 µg/mL), F1–F9-excluding F7 (HPLC fractions of C2F at concentrations of 163 µg/mL), F1–F9 (each an HPLC fraction of C2F at concentrations of 163 µg/mL) on HCT 116 cells measured as level of IL-8 (ng/mL). HCT116 cells were seeded (50,000 per well) in triplicate in 500 µL growing media and incubated for 24 h at 37°C in a humidified 5% CO₂–95% air atmosphere. Cells were treated with 300 ng/mL TNFα and 50 µL of *C. sativa* ethanol extract of C2F or fractions for 4 h. Nontreated are the cells without TNFα and treatments. Levels of IL-8 were measured from the supernatant using a commercial kit. Values (ng/mL) were calculated relative to a TNFα-treated control. (C) Determination of HCT116 cell viability using Alamar Blue fluorescence (resazurin assay) as a function of live cell number. Cells were seeded and treated as described in (B). Next, the cells were incubated with Alamar Blue for 2 h. Relative fluorescence at the excitation/emission of 544/590 nm was measured. Values were calculated as percentage of live cells relative to the nontreated (cells without TNFα and treatments) control after reducing the autofluorescence of Alamar Blue without cells. Error bars indicate ±SE (n = 3). * *** Indicate data statistically significantly different in comparison with the control (TNFα treated cells) at *p* ≤ 0.01 and ***p* ≤ 0.0001, respectively. Levels with different letters are significantly different from all combinations of pairs by Tukey’s HSD.
**FIG. 4.** (A) Anti-inflammatory activity of *C. sativa* ethanolic extracts (C2F; 163 µg/mL), F7 at three different concentrations (an HPLC fraction of C2F at concentrations of 142, 163, and 190 µg/mL), fractions F1–F9-excluding F7 (F1–F9-exc F7) at two concentrations (HPLC fractions of C2F at concentrations of 163 and 190 µg/mL), combination of each concentration of F1–F9-excluding F7 along with each concentration of F7 on HCT 116 cells measured as level of IL-8 (ng/mL). HCT116 cells were seeded (50,000 per well) in triplicate in 500 µL growing media and incubated for 24 h at 37°C in a humidified 5% CO₂–95% air atmosphere. Cells were treated with 300 ng/mL TNFα and 50 µL of *C. sativa* ethanol extract of C2F or fractions for 4 h. Nontreated are the cells without TNFα and treatments. Levels of IL-8 were measured from the supernatant using a commercial kit. Values (ng/mL) were calculated relative to a TNFα-treated control. (B) Determination of HCT116 cell viability using Alamar Blue fluorescence (resazurin assay) as a function of live cell number. Cells were seeded and treated as described in (A). Next, the cells were incubated with Alamar Blue for 2 h. Relative fluorescence at the excitation/emission of 544/590 nm was measured. Values were calculated as percentage of live cells relative to the nontreated (cells without TNFα and treatments) control after reducing the autofluorescence of Alamar Blue without cells. Error bars indicate ± SE (n = 3). **, *** Indicate data statistically significantly different in comparison with the control (TNFα-treated cells) at p ≤ 0.001 and p ≤ 0.0001, respectively. Levels with different letters are significantly different from all combinations of pairs by Tukey’s HSD.
GPR55 receptor antagonist significantly reduces the anti-inflammatory activity of F7, whereas CB2 receptor antagonist significantly increases HCT116 cell proliferation.

To determine whether activity of fractions of C2F in HCT116 cells is conferred via the CBs or GPR55 receptors, we determined the effect of CB1, CB2, and GPR55 receptor antagonists (rimonabant, SR144528 and CID16020046, respectively) on their anti-inflammatory or cytotoxic activities. CB1 and CB2 receptor antagonists did not change the anti-inflammatory activity of F7 or F1–F9 (Fig. 6A). However, addition of GPR55 antagonist led to a significant reduction in activity and to an increase in IL-8 levels in these treatments (Fig. 6A). Addition of GPR55 antagonist did not change IL-8 level in control (Fig. 6A). As for the cytotoxic activity, a significant reduction in F1–F9-excluding F7 with addition of F7 (163 and 190 μg/mL, respectively) activity was found for CB2 antagonist. However, CB2 antagonist increases cell number even in the control (Fig. 6B), suggesting that it counteracts the fractions’ activity by inducing HCT116 cell proliferation (Fig. 6B).

Transcripts for CB1, CB2, and GPR55 were detected by qPCR in HCT116 cells. Expression of CB2 and GPR55 was significantly increased on treatment with TNFα in these cells (values are the steady-state level of gene expression in TNFα-treated vs. nontreated cells; Table 2).

CBD reduces inflammation only at lower concentration yet its cytotoxic activity is dose dependent.

The fraction of C2F containing CBG, CBD, and CBDA (F2) did not show any anti-inflammatory activity in HCT116 cells in terms of IL-8 reduction (Fig. 3A). This is in contrast to several publications that have suggested that CBD is the main anti-inflammatory compound for IBD (reviewed by Esposito et al.27). To further examine CBD activity, we determined the anti-inflammatory and cytotoxic activity of pure CBD (purity was verified by HPLC, not shown) in
FIG. 6. (A) Anti-inflammatory activity of *C. sativa* F7 at three different concentrations (an HPLC fraction of C2F at concentrations of 190 µg/mL), fractions F1–F9-excluding F7 (F1–F9-exc F7; HPLC fractions of C2F at concentrations of 163 µg/mL), combination of F1–F9-excluding F7 along with F7 measured as level of IL-8 on HCT116 cells, with and without antagonists to CB1, CB2, and GPR55 receptors (antagonists at a concentration of 20 µM, CB1 receptor antagonist rimonabant; CB2, CB2 receptor antagonist SR144528; GPR55, GPR55 antagonist CID16020046). HCT116 cells were seeded (50,000 per well) in triplicate in 500 µL growing media and incubated for 24 h at 37°C in a humidified 5% CO₂–95% air atmosphere. Cells were treated with 300 ng/mL TNFα and 50 µL of *C. sativa* ethanol extract of C2F fractions for 4 h. Treatments with F7, F1–F9, and combination of fractions without antagonists served as a positive control (Con). Nontreated are the cells without TNFα and treatments. Levels of IL-8 were measured from the supernatant using a commercial kit. Values (ng/mL) were calculated relative to control.

(B) Determination of HCT116 cell viability using Alamar Blue fluorescence (resazurin assay) as a function of cytotoxic effect. HCT116 cells were seeded (50,000 per well) in triplicate in 500 µL growing media and incubated for 24 h at 37°C in a humidified 5% CO₂–95% air atmosphere. Cells were seeded and treated as described in (A). Next, the cells were incubated with Alamar Blue for 2 h. Relative fluorescence at the excitation/emission of 544/590 nm was measured. Values were calculated as percentage of live cells relative to the nontreated (cells without TNFα and treatments) control after reducing the autofluorescence of Alamar Blue without cells. Error bars indicate ±SE (n = 3). *, ** indicate data statistically significantly different in comparison with the control (TNFα-treated cells) at p ≤ 0.01 and p ≤ 0.0001, respectively. Levels with different letters are significantly different from all combinations of pairs by Tukey’s HSD. CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2.
HCT116, HT29, and CaCO2 cells. Treatment with purified CBD at different concentrations (16–252 μg/mL) leads to a significant reduction in IL-8 levels at lower concentrations of CBD (Supplementary Fig. S3A). Yet, no anti-inflammatory activity for CBD was determined for the higher CBD concentrations in HCT116 cells (Supplementary Fig. S3A). CBD was active in reduction of IL-8 levels in CaCO2 and HT29 cells (Supplementary Fig. S3A). However, treatments with CBD lead to a dose-dependent cell death in HCT116 and in CaCO2 cells, and to a lesser extent in HT29 cells (Supplementary Fig. S3B).

Treatment with C. sativa extracts C2F and F7 leads to reduction in IL-8 levels in patient colon tissue

Since cell lines do not fully reflect the conditions in colon tissue, we further verified C2F and F7 inflammation-reducing activity in biopsies of colon tissue taken from IBD patients. Biopsies were maintained ex vivo and the levels of IL-8 and IL-6 were determined in nontreated versus C2F- and F7-treated tissue. Treatment with C2F reduced significantly both IL-8 and IL-6 levels compared to nontreated controls (n = 29). These results confirmed the anti-inflammatory effect of C2F and F7 on colon tissues derived from IBD patients (Fig. 7).

TREATMENT OF HCT116 CELLS AND BIOPSIES WITH C. SATIVA EXTRACTS C2F AND F7 LEADS TO REDUCTION IN MMP9 AND COX2 EXPRESSION

MMP9 expression is induced in the large intestine of IBD patients (reviewed by Wang and DuBois29) and MMP9 is among the predominant proteinases expressed in the gut mucosa during active IBD, associated with disease severity.29 The steady-state levels of MMP9 and COX2 expression were examined as markers for inflammation level in HCT116 cells and colon biopsies of IBD patients (four UC and one CD). Expression of both COX2 and MMP9 was significantly induced in HCT116 cells treated with TNFα and significantly reduced by treatment with C2F and F7. F7 was more effective at reducing COX2 expression than C2F (Fig. 8A). In colon tissues, expression of both COX2 and MMP9 was downregulated by C2F and F7 treatments (Fig. 8B). As with the cell lines, F7 was more effective than C2F at reducing COX2 expression (Fig. 8B).

DISCUSSION

The present study suggests that the anti-inflammatory activity of Cannabis extracts on colon epithelial cells derives from a fraction of the extract that contains THCA. This conclusion is based on several lines of evidence. First, fresh flower ethanolic extracts of C. sativa led to reduction of IL-8 levels in HCT116, HT29, and CaCO2 colon cell lines, determined as reduction in IL-8 secretion. Second, fractionation of the fresh

### Table 2. Relative Gene Expression in HCT116 Cells

<table>
<thead>
<tr>
<th>Gene</th>
<th>Mean relative expression</th>
<th>Std Err</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td>CB1</td>
<td>1.31</td>
<td>0.19</td>
<td>AB</td>
</tr>
<tr>
<td>CB2</td>
<td>5.84</td>
<td>1.04</td>
<td>A</td>
</tr>
<tr>
<td>GPR55</td>
<td>5.26</td>
<td>1.57</td>
<td>B</td>
</tr>
</tbody>
</table>

CB1, CB2, and GPR55 gene expression was measured after overnight treatment of the cells with TNFα. Values of gene transcripts were determined as a ratio between target genes (CB1, CB2, and GPR55) versus a reference gene (GAPDH), in TNFα-treated versus untreated cells using the 2^ΔΔCt method.

CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2; TNFα, tumor necrosis factor alpha.
flower extract yielded only one fraction, F7, which retained activity. Third, chemical analysis showed that F7 contains mainly THCA. Also, a combination of F7 with the other F1–F9 fractions led to anti-inflammatory activity in HCT116 cells similar to that of the whole extract. Furthermore, under the examined conditions, F7 did not show cytotoxic activity, further suggesting that under the examined conditions, F7 activity is anti-inflammatory and does not derive simply from cell death.

As previously indicated, THC is considered to be one of the most active compounds in *C. sativa*. However, other phytocannabinoids, including CBG, CBN, and THCV, are now known to have therapeutic effects. As for THCA, other cell-based experiments have demonstrated its immunomodulatory, anti-inflammatory, neuroprotective, and antineoplastic activity (reviewed in Moreno-Sanz). For example, in lipopolysaccharide-activated U937 macrophages and peripheral blood macrophages, THCA-A inhibits the release of TNFα and COX1 and COX2 expression in a dose-dependent manner and prostaglandin production.

In agreement, C2F and F7 were found to inhibit the expression of COX2. COX1 and COX2 catalyze the production of prostaglandins from arachidonic acid, and prostaglandins are known to be important in mediating the inflammatory process. COX2 is an immediate early response gene induced mainly at sites of inflammation in response to inflammatory stimuli, whereas it is normally absent from most cells. It is induced in the large intestine of IBD patients and in inflamed tissues of an IL-10-deficient mouse model of IBD (reviewed by Wang and DuBois). Reduction of COX2 has been suggested as a major target for the treatment of IBD (e.g., El Miedany et al.). In agreement, in *in vitro* enzyme-based COX1/COX2 inhibition assay and in HT29 cell line, COX1 and COX2 enzyme activity was inhibited by THCA, however, only in the high millimolar concentration range.

Our results showed that C2F and F7 inhibit the expression of MMP9 as well. MMP9 is among the
We found that CB2 receptor antagonist led to an increase in the percentage of live cells even in the absence of C. sativa treatment, suggesting that CB2 activity may be negatively involved with cell proliferation. However, CB2 was shown to be expressed with great intensity in epithelial cells of colorectal cancer tumor and correlated with tumor growth and disease progression. Moreover, its expression was suggested to be a marker for poor prognosis. Also, Romano et al. found that Cannabis extract with high content of CBD inhibits colorectal cancer cell proliferation and attenuates colon carcinogenesis. This activity involved CB1 and CB2 receptor activation.

GPR55, activated by phytocannabinoids and endocannabinoids, is widely expressed in several tissues, including the GI and in different human innate and adaptive immune cells. Our results suggest that the anti-inflammatory activity of F7 is affected by GPR55 receptor antagonists, suggesting that the anti-inflammatory activity of F7 is mediated, at least partially, via GPR55. In contrast, the findings that GPR55 negatively affects the ability of monocytes to phagocytose, enhances IL-12 and TNFα production, and that pharmacological blockade of GPR55 reduces intestinal inflammation in mice by reducing leukocyte migration and activation, positioning GPR55 with a proinflammatory role.

Our results also show a dose-dependent cytotoxic activity for CBD in all three examined cell lines, in agreement to other studies suggesting CBD to be cytotoxic (e.g., ChoiPark et al.). However, we found anti-inflammatory activity for CBD only for the low concentrations, and in a bell-shaped rather than dose-dependent manner. At high CBD concentrations, even a proinflammatory effect was detected. Similar results for bell-shaped anti-inflammatory activity were found for CBD in an animal model of inflammation. Yet, CBD is still considered to be a strong anti-inflammatory agent. Our results suggest that in a nonpsychoactive treatment for IBD, THCA should be used rather than CBD.

An important advantage of using THCA (present in F7) is its lack of narcotic activity. This is due to two pharmacological traits: decreased central nervous system penetration due to the presence of a carboxylic group and a probable inability to convert to THC in vivo. Hence, the use of C. sativa extract that contains THCA could have major implications for the medical use of THCA, the relevant fraction in predominant proteinases expressed in the gut mucosa during active IBD and it is associated with disease severity. In addition, MMP9 levels are significantly higher in active IBD and in UC compared to CD. Indeed, in UC patients, fecal MMP9 levels are significantly correlated with several measurement parameters, such as Mayo score, endoscopic score, and serum C-reactive protein levels, suggesting that it is a good selective marker for evaluation of disease activity in UC patients. The inhibition of MMP9 expression by C2F and F7 in both cell lines and IBD patients (three UC and one CD) provides another indication of their possible efficacy against colon inflammation.

Perhaps even more significant, inhibition of COX2 and reduction of prostaglandin production have been proposed to play an important role in the inhibition of colon cancer development. Importantly, COX2 expression is elevated in up to 90% of colorectal carcinomas and is correlated with poor prognosis, whereas it has been shown in mice that for cancer therapy, selective COX2 inhibitors may enhance the activity of antiangiogenic agents against pre-established metastases.

In this light, our findings that a certain combination of F7 with the other fractions highly induces cell death suggest interaction between THCA and other C. sativa compounds for this activity. Interactions between C. sativa-derived compounds were notified before for different activities. Practically, using certain combinations of C. sativa compounds may further potentiate the use of C. sativa as an anticancer drug.

Phytocannabinoids as well as endocannabinoids bind to target receptors and activate various signaling pathways thereby affecting several biological processes. The main receptors for endocannabinoids are CB1 and CB2 (reviewed by Chiurchiu et al.). CB1 and CB2 are expressed in different tissues and cells. CB1 is mainly expressed in the nervous system and is involved in the regulation of cognitive, memory, motor functions, and analgesia. CB2 is expressed by the cells of the immune system and is associated with the modulation of different immune functions (reviewed by Chiurchiu et al.). CB2 was also found in additional tissues, including epithelial cells of the colon. Upregulation of CB2 is associated with chronic inflammation of the nervous system and modulation of intestinal inflammation.
combination with other fractions or, alternatively, raw, unheated Cannabis preparations. Such preparations might promote more precise treatment with medical Cannabis for IBD patients, maximizing Cannabis’s therapeutic gain while minimizing the undesirable psychoactive side effects. Our results further underscore the need to allocate the right treatment with the right compounds for each medical indication treated by Cannabis.

Acknowledgment
Research was performed under the authorization of IMCA (Israel Medical Cannabis Agency) for research in medical cannabis.

Author Disclosure Statement
O.S. was paid as an employee of PLANTEXT, Israel. For other authors, no competing financial interests exist.

References

**Abbreviations Used**
- CB1 = cannabinoid receptor type 1
- CB2 = cannabinoid receptor type 2
- CBC = cannabichromene
- CBD = cannabidiol
- CBDA = cannabidiolic acid
- CBG = cannabigerol
- CBGA = cannabigerolic acid
- CBN = cannabinol
- CD = Crohn’s disease
- COX2 = cyclooxygenase-2
- Dex = dexamethasone
- DMEM = Dulbecco’s modified Eagle’s medium
- ELISA = enzyme-linked immunosorbent assay
- ESI = electrospray ionization
- F7 = fraction 7
- GI = gastrointestinal
- HPLC = high-performance liquid chromatography
- IBD = inflammatory bowel disease
- IL = interleukin
- MMP9 = metalloproteinase-9
- MS = mass spectrometry
- NT = nontreated
- RT = retention time
- SE = standard error
- THC = Δ9-tetrahydrocannabinol
- THCA = Δ9-tetrahydrocannabinolic acid
- THCV = Δ9-tetrahydrocannabivarin
- TNFα = tumor necrosis factor alpha
- UC = ulcerative colitis